RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/35226042http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35226042http://www.w3.org/2000/01/rdf-schema#comment"Delivery of biotherapeutics across the blood-brain barrier (BBB) is a challenge. Many approaches fuse biotherapeutics to platforms that bind the transferrin receptor (TfR), a brain endothelial cell target, to facilitate receptor-mediated transcytosis across the BBB. Here, we characterized the pharmacological behavior of two distinct TfR-targeted platforms fused to iduronate 2-sulfatase (IDS), a lysosomal enzyme deficient in mucopolysaccharidosis type II (MPS II), and compared the relative brain exposures and functional activities of both approaches in mouse models. IDS fused to a moderate-affinity, monovalent TfR-binding enzyme transport vehicle (ETV:IDS) resulted in widespread brain exposure, internalization by parenchymal cells, and significant substrate reduction in the CNS of an MPS II mouse model. In contrast, IDS fused to a standard high-affinity bivalent antibody (IgG:IDS) resulted in lower brain uptake, limited biodistribution beyond brain endothelial cells, and reduced brain substrate reduction. These results highlight important features likely to impact the clinical development of TfR-targeting platforms in MPS II and potentially other CNS diseases."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.org/dc/terms/identifier"doi:10.1084/jem.20211057"xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Harris J.M."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Fang M."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Kim D.J."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Dennis M.S."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Wang J."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Shan L."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Giese T."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Gunasekaran K."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Chan D."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Calvert M.E.K."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Duque J."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Watts R.J."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Lewcock J.W."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Nguyen H.N."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Liang N."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Scearce-Levie K."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Dugas J.C."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Ullman J.C."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Troyer M.D."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Chau R."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Diaz D."xsd:string
http://purl.uniprot.org/citations/35226042http://purl.uniprot.org/core/author"Arguello A."xsd:string